Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate ...
Fierce Biotech

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive ...
Fierce Biotech

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) ...
Drug Target Review

Bispecific EGFR/EphA2-targeting ADC shows promise in colorectal cancer

PBS293-MMAE targets EGFR and EphA2, two proteins shown to be co-expressed in colorectal cancer cells. While EGFR is a clinically validated target in colorectal cancer, therapeutic antibodies such as ...
MarketWatch

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...
Hosted on MSN

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult ...
Morningstar

Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)

CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug ...
MedCity News

Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug

Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression on the surface of cells in gastrointestinal cancers makes it an attractive ...

Antibody-Drug Conjugate Drug Market Landscape Report 2026 Featuring 34 Key Players - Past and Emerging Trends, Partnership Opportunities, Drug Pipelines, and Leading Companies

The report identifies key opportunities in Antibody-Drug Conjugates through insights on past trends, drug pipelines, and leading companies. It serves investors, new entrants, and pharma firms looking ...